Asset Details
Do you wish to reserve the book?
Surrogate endpoint metaregression: useful statistics for regulators and trialists
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Surrogate endpoint metaregression: useful statistics for regulators and trialists
Do you wish to request the book?
Surrogate endpoint metaregression: useful statistics for regulators and trialists
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Surrogate endpoint metaregression: useful statistics for regulators and trialists
2024
Overview
The main purpose of using a surrogate endpoint is to estimate the treatment effect on the true endpoint sooner than with a true endpoint. Based on a metaregression of historical randomized trials with surrogate and true endpoints, we discuss statistics for applying and evaluating surrogate endpoints.
We computed statistics from 2 types of linear metaregressions for trial-level data: simple random effects and novel random effects with correlations among estimated treatment effects in trials with more than 2 arms. A key statistic is the estimated intercept of the metaregression line. An intercept that is small or not statistically significant increases confidence when extrapolating to a new treatment because of consistency with a single causal pathway and invariance to labeling of treatments as controls. For a regulator applying the metaregression to a new treatment, a useful statistic is the 95% prediction interval. For a clinical trialist planning a trial of a new treatment, useful statistics are the surrogate threshold effect proportion, the sample size multiplier adjusted for dropouts, and the novel true endpoint advantage.
We illustrate these statistics with surrogate endpoint metaregressions involving antihypertension treatment, breast cancer screening, and colorectal cancer treatment.
Regulators and trialists should consider using these statistics when applying and evaluating surrogate endpoints.
Publisher
Elsevier Inc,Elsevier Limited
Subject
/ Antihypertensive Agents - therapeutic use
/ Breast Neoplasms - drug therapy
/ Colorectal Neoplasms - drug therapy
/ Data Interpretation, Statistical
/ Endpoint Determination - methods
/ Endpoint Determination - statistics & numerical data
/ Female
/ Humans
/ Labeling
/ Randomized Controlled Trials as Topic - methods
/ Randomized Controlled Trials as Topic - standards
/ Randomized Controlled Trials as Topic - statistics & numerical data
